Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2014 /
Results of HD2000 trial comparing combination therapies in advanced-stage Hodgkin's lymphoma

6th - 9th Dec 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.12.14
Views: 1577

Prof Massimo Federico - University of Modena and Reggio Emilia, Modena, Italy

Prof Massimo Federico speaks to ecancertv at ASH 2014 about the results of the HD2000 trial, which compared the effects of multiple types of combination therapies on patients with advanced-stage Hodgkin lymphoma. Combination therapy ABVD was trialled alongside BEACOPP and Copp/EBV/CAD.

He discusses the long-term outcome and toxicity of the treatments, finding that none of the treatment arms demonstrated superiority over one another.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation